Eledon Pharmaceuticals (ELDN) Liabilities and Shareholders Equity (2013 - 2026)

Eledon Pharmaceuticals has reported Liabilities and Shareholders Equity for 14 years, with the latest figure at $146.7 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 9.08% year-over-year to $146.7 million; the trailing twelve-month figure through Mar 2026 stood at $590.4 million (up 2.91% YoY), and the FY2025 full-year result was $169.0 million, down 4.73% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $146.7 million, down from $169.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $177.4 million in Q4 2024, with the low at $80.8 million in Q1 2024.
• Historically, Liabilities and Shareholders Equity has averaged $128.1 million across 5 years, with a median of $129.9 million in 2025.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity plunged 49.0% — and 2025, when it soared 99.59%.
• Eledon Pharmaceuticals' Liabilities and Shareholders Equity stood at $92.8 million in 2022, then declined by 4.02% to $89.1 million in 2023, then surged by 99.18% to $177.4 million in 2024, then dropped by 4.73% to $169.0 million in 2025, then declined by 13.22% to $146.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $146.7 million (Q1 2026), $169.0 million (Q4 2025), and $129.9 million (Q3 2025), per Business Quant data.